JP Morgan Chase
ACET icon

JP Morgan Chase’s Adicet Bio ACET Stock Holding History

JP Morgan Chase’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49 Sell
8
-4
-33% -$30 ﹤0.01% 7362
2025
Q4 		$101 Sell
12
-36
-75% -$398 ﹤0.01% 7212
2025
Q3 		$625 Hold
48
– – ﹤0.01% 7034
2025
Q2 		$470 Sell
48
-25
-34% -$264 ﹤0.01% 6703
2025
Q1 		$883 Sell
73
-9,332
-99% -$133K ﹤0.01% 6641
2024
Q4 		$145K Buy
9,405
+4,383
+87% +$82.7K ﹤0.01% 5606
2024
Q3 		$116K Buy
5,022
+4,974
+10,363% +$111K ﹤0.01% 5638
2024
Q2 		$933 Sell
48
-3,655
-99% -$97.9K ﹤0.01% 6628
2024
Q1 		$139K Buy
3,703
+2,464
+199% +$102K ﹤0.01% 5531
2023
Q4 		$37.5K Sell
1,239
-510
-29% -$11.1K ﹤0.01% 6089
2023
Q3 		$38.3K Buy
1,749
+136
+8% +$4.8K ﹤0.01% 5886
2023
Q2 		$62.7K Buy
1,613
+155
+11% +$13.7K ﹤0.01% 5654
2023
Q1 		$134K Buy
1,458
+345
+31% +$43.3K ﹤0.01% 5285
2022
Q4 		$159K Sell
1,113
-34
-3% -$8.48K ﹤0.01% 5146
2022
Q3 		$261K Buy
1,147
+88
+8% +$22.3K ﹤0.01% 4818
2022
Q2 		$247K Buy
1,059
+11
+1% +$2.42K ﹤0.01% 4959
2022
Q1 		$335K Buy
1,048
+160
+18% +$36.8K ﹤0.01% 4927
2021
Q4 		$247K Buy
888
+153
+21% +$26.3K ﹤0.01% 5229
2021
Q3 		$93K Buy
735
+140
+24% +$17.4K ﹤0.01% 5601
2021
Q2 		$98K Buy
+595
New +$121K ﹤0.01% 5551
2021
Q1 		– Sell
-24
Closed -$5K – 6011
2020
Q4 		$5K Buy
+24
New +$4.92K ﹤0.01% 5443
2020
Q3 		– Hold
0
– – – 5438
2020
Q2 		– Sell
-561
Closed -$110K – 5325
2020
Q1 		$65K Sell
561
-54
-9% -$8.02K ﹤0.01% 4649
2019
Q4 		$103K Sell
615
-56
-8% -$28.4K ﹤0.01% 4884
2019
Q3 		$665K Buy
671
+32
+5% +$35.7K ﹤0.01% 4047
2019
Q2 		$734K Sell
639
-27
-4% -$24.5K ﹤0.01% 4031
2019
Q1 		$510K Sell
666
-45
-6% -$40.9K ﹤0.01% 4201
2018
Q4 		$686K Sell
711
-44
-6% -$57.9K ﹤0.01% 3963
2018
Q3 		$1.28M Sell
755
-669
-47% -$873K ﹤0.01% 3752
2018
Q2 		$1.46M Sell
1,424
-66
-4% -$71.1K ﹤0.01% 3619
2018
Q1 		$1.6M Buy
+1,490
New +$2.73M ﹤0.01% 3408

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

JP Morgan Chase's ACET Position: Q1 2026 in Review

JP Morgan Chase reduced its Adicet Bio (ACET) stake by 33% in Q1 2026, selling an estimated $30 and leaving 8 shares worth $49. The position accounts for ﹤0.01% of the portfolio, ranked #7362.

JP Morgan Chase first reported a position in ACET in Q1 2018 and has held it in 30 quarters since. The position peaked at $1.6M in Q1 2018. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • JP Morgan Chase held 8 shares of Adicet Bio worth $49 as of Q1 2026.
  • JP Morgan Chase sold 4 Adicet Bio shares in Q1 2026, an estimated $30.
  • Adicet Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7362 holding.
  • JP Morgan Chase first reported a position in Adicet Bio in Q1 2018 and has held it in 30 quarters since.
  • JP Morgan Chase's Adicet Bio position peaked at $1.6M in Q1 2018.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.